NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 258,100 shares, a decrease of 32.6% from the October 31st total of 383,000 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average trading volume of 237,200 shares, the days-to-cover ratio is currently 1.1 days.

Hedge Funds Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd bought a new stake in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned 0.24% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ:NRSN traded up $0.05 during trading hours on Friday, hitting $0.98. 323,423 shares of the company’s stock traded hands, compared to its average volume of 144,181. The firm has a market capitalization of $13.40 million, a P/E ratio of -1.15 and a beta of 1.58. The business has a fifty day moving average price of $1.17 and a 200-day moving average price of $1.04. NeuroSense Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.33.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.